Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc.

6,460.10
MXN
+2,387.06
(+58.61%)
15.79EPS
Feb 24Next Earn
Charles River Laboratories International, Inc.
BIVA:CRL
(Institutional Stock Exchange)

Recent

price

6,460.10

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
18.12
22.48
23.58
24.41
27.83
29.32
35.76
39.12
47.26
53.79
59.01
70.39
78.25
80.61
78.82
81.01
82
Revenue per Share
-5.38
2.16
2.03
2.15
2.72
3.21
3.29
2.6
4.72
5.17
7.35
7.77
9.57
9.27
0.2
-2.91
0.83
Basic EPS, GAAP
2.7
4.04
4.34
4.34
5.38
6.56
6.74
6.7
9.2
9.87
11.03
15.13
12.19
13.35
14.3
14.88
12.83
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
12.18
10.75
12.46
13.48
14.2
15.7
17.67
22.05
27.33
33.4
42.49
50.21
58.42
70.06
67.69
64.3
67.4
Book Value per Share
6.52
4.8
6.37
6.85
3.64
0.29
-7.29
-2.73
-11.22
-12.17
-9.69
-24.53
-16.27
-7.06
-2.12
1.23
-2
Tangible Book Value per Share
63
51
48
48
47
46
47
47
48
49
50
50
51
51
51
50
48
Basic Weighted Avg Shares
1,133
1,143
1,130
1,166
1,298
1,363
1,681
1,858
2,266
2,621
2,924
3,540
3,976
4,129
4,050
4,015
3,977
Sales/Revenue/Turnover
11.28
15.91
14.68
12.99
13.69
15.14
14.13
15.52
14.62
13.4
14.8
16.66
16.37
14.95
10.92
9.99
13.45
Operating Margin (%)
94
85
81
97
96
95
127
131
162
198
235
266
304
314
362
403
285
Depreciation Expense
-337
110
97
103
127
149
155
123
226
252
364
391
486
475
10
-144
40
Net Income, GAAP
- -
12.92
21.29
23.79
26.84
22.2
29.98
57.71
19.33
16.45
18.3
17.03
20.93
17.36
72.84
- -
- -
Effective Tax Rate (%)
-29.7
9.59
8.61
8.82
9.76
10.95
9.2
6.64
9.99
9.61
12.46
11.04
12.23
11.49
0.25
-3.59
1.01
Profit Margin (%)
293
209
143
306
285
247
227
363
340
311
361
241
347
554
409
327
446
Working Capital
670
703
527
642
741
846
1,208
1,114
1,637
1,966
2,085
2,917
3,097
3,066
2,724
2,570
2,849
LT Debt
689
527
603
665
704
766
854
1,064
1,338
1,666
2,144
2,592
3,024
3,659
3,508
3,211
3,275
Total Equity
- -
11.42
10.27
8.75
9.16
10.27
8.86
5.58
10.12
8.7
8.79
9.89
8.81
7.94
0.95
- -
- -
Return on Invested Capital (%)
- -
11.1
9.78
9.04
9.55
10.26
9.28
6.23
10.56
8.98
10.85
9.03
9.03
9.06
0.46
- -
- -
Return on Capital (%)
-32.64
18.07
17.28
16.56
19.3
21.25
19.72
13.11
19.16
17.07
19.43
16.82
17.65
14.44
0.29
-4.36
1.21
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
- -
- -
LT Borrowings
2,663
2,620
2,435
LT Finance Leases
393
408
414
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
48
48
48
Market Capitalization
- -
- -
- -

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,489
1,529
1,535
Cash, Cash Equivalents & STI
192
192
200
Accounts Receivable, Net
513
525
547
Inventories
360
346
320
Total Current Liabilities
1,094
1,135
1,089
Payables & Accruals
506
521
430
ST Debt
- -
- -
- -
Deferred Revenue
194
203
204

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
16.11%
9.2%
-8.46%
Free Cash Flow
10.45%
7.77%
0.42%
Net Income, GAAP
-144.75%
-314.06%
-1,501.75%
Sales/Revenue/Turnover
11.75%
6.9%
-0.85%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,012
1,026
1,010
1,003
4,050
2025
984
1,032
1,005
994
4,015
2026
996
1,004
983
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.31
1.75
1.34
-4.22
0.2
2025
0.5
1.06
1.11
-5.62
-2.91
2026
-0.3
-0.03
6.97
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Charles River Laboratories International, Inc. (NYSE: CRL) provides essential drug discovery, non-clinical development, safety assessment, and manufacturing solutions to the pharmaceutical, biotechnology, and medical device industries worldwide. Founded in 1947 and headquartered in Wilmington, Massachusetts, the company operates through three primary segments: Research Models and Services (RMS), which supplies research animal models including genetically modified rodents, preconditioned animals, and related services such as genetic monitoring and vivarium management; Discovery and Safety Assessment (DSA), which delivers early-stage discovery studies for target identification, compound validation, in vivo pharmacology, and comprehensive safety testing encompassing toxicology, pathology, bioanalysis, drug metabolism, pharmacokinetics, and safety pharmacology; and Manufacturing Solutions, which offers in vitro quality control testing for sterile and non-sterile pharmaceuticals and consumer products, specialized biologics testing, avian vaccine services including specific-pathogen-free eggs and chickens, and microbial solutions for endotoxin detection. With facilities spanning the United States, Europe, Canada, Asia Pacific, and other international regions, Charles River supports clients from concept to commercialization, including advanced modalities like cell and gene therapies through its integrated CDMO capabilities. Recent developments include a strategic exploration of collaboration with BioTech Social announced in late 2024 to integrate crowdfunding via the BioTech Funding Portal into its Charles River Incubator Program (CIP) and Cell and Gene Therapy Accelerator Program (CAP), both launched in 2024 to provide regulatory expertise, lab space, and funding pathways for early-stage developers; a $13 million expansion of its microbial solutions facility in Charleston County, South Carolina, in August 2025 to enhance quality control testing capacity; alliances with the Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles in 2025 to advance oncology manufacturing and Phase I clinical trial materials for pediatric solid tumors; renewal of its partnership with the CHDI Foundation to bolster Huntington's disease research; and ongoing portfolio enhancements in plasmid DNA, viral vectors, and cell therapy services to meet rising demand in advanced therapies.

Company News

  • Alpha Teknova (NASDAQ:TKNO) versus Charles River Laboratories International (NYSE:CRL) Critical Analysis

  • Commonwealth Equity Services LLC Buys 31,177 Shares of Charles River Laboratories International, Inc. $CRL

  • Ariel Small Cap Value Q3 2026 Portfolio Activity

  • GMRS vs. CRL: Which Stock Should Value Investors Buy Now?

  • Charles River Strengthens Global Microbial Solutions Network Through Investments in Manufacturing, Customer Support, and Sustainability

  • 5,106 Charles River Laboratories International, Inc. $CRL Shares Purchased by Brighton Jones LLC

  • Tigermed to Participate in the Privatization of Frontage Holdings Corporation and Divest Its Overseas Laboratory Services Business

  • Here's Why Charles River Laboratories (CRL) is a Strong Momentum Stock

  • Unlocking Charles River (CRL) International Revenues: Trends, Surprises, and Prospects

  • Charles River Laboratories to Acquire Frontage's Bioanalysis and DMPK Businesses

  • Charles River Laboratories International Q3 Earnings Call Highlights

  • Boston Trust Walden Corp Sells 37,537 Shares of Charles River Laboratories International, Inc. $CRL

  • Charles River Laboratories International, Inc. (CRL) Q3 2026 Earnings Call Transcript

  • Charles River Q3 Earnings & Revenues Top Estimates, Stock Rises

  • Charles River (CRL) Reports Q3 Earnings: What Key Metrics Have to Say

  • Charles River Laboratories (CRL) Tops Q3 Earnings and Revenue Estimates

  • Charles River Laboratories Announces Third-Quarter 2026 Results

  • Charles River's Q3 Earnings on Deck: What's in Store for the Stock?

  • Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?

  • Ariel Appreciation Fund Q3 2026 Scorecard: Buys, Sells, And Standouts